Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 9Genitourinary 6Head & Neck 5Gynecologic 4Thoracic 3Sarcoma 2Dermatologic 2CNS 2Tumor-Agnostic 1Other solid neoplasm 1Lymphoid 1

Conditions

Solid Tumors 1

Interventions

pembrolizumab 33Injections 28Pemetrexed 15Interviews as Topic 15Carboplatin 14tislelizumab 13Cisplatin 13Specimen Handling 12Bevacizumab 11atezolizumab 10Nivolumab 10Practice Guidelines as Topic 9Educational Status 9Cyclophosphamide 9Standard of Care 8Oxaliplatin 8Fluorouracil 8fludarabine 7Methods 7Early Intervention, Educational 7Docetaxel 7Cetuximab 7Capecitabine 7toripalimab 6sotorasib 6Paclitaxel 6Leucovorin 6olaparib 5Platinum 5Ipilimumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
spartalizumab × Other solid neoplasm × 90 days × Clear all
NCT05155332 2026-05-20

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Boehringer Ingelheim

Phase 1 Suspended
190 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡